Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ubidecarenone,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BERG To Conduct Phase Two Trial For Treatment Of Deadly Glioblastoma Multiforme [GBM]
Details : Preclinical evidence in an aggressive orthotopic model of GBM suggests that pre-treatment (priming) followed by co-administration of BPM31510 in combination with standard of care, such as radiation and chemotherapy, led to an increase overall survival ra...
Product Name : BPM31510
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : Ubidecarenone,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ubidecarenone,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abstract titled "Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM31510-IV treatment in advanced glioblastoma multiforme patients" will be presented at the ASCO meeting.
Product Name : BPM31510
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : Ubidecarenone,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ubidecarenone
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : AdventHealth
Deal Size : Undisclosed
Deal Type : Collaboration
BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research
Details : The partnership is comprised of separate investigations that employ BERG’s Interrogative Biology® platform to examine potential biomarker signatures of age-related disease. This also includes Phase II trial of BPM31510 on platelet and skeletal muscle ...
Product Name : BPM31510
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : Ubidecarenone
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : AdventHealth
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ubidecarenone,Gemcitabine HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BPM 31510-IV (ubidecarenone) also known as coenzyme Q10 used in advanced refractory pancreatic ductal adenocarcinoma and identified two potential biomarkers overall survival and progressive disease.
Product Name : BPM31510
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 18, 2020
Lead Product(s) : Ubidecarenone,Gemcitabine HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ubidecarenone,Gemcitabine HCl
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Initial results showed efficacy in patient's refractory to chemotherapy regimens and identification of potential biomarkers of survival guided by the use of the BERG Interrogative Biology® platform.
Product Name : BPM31510
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Ubidecarenone,Gemcitabine HCl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable